The Impact of Preexisting or Acquired Kaposi Sarcoma Herpesvirus Infection in Kidney Transplant Recipients on Morbidity and Survival
C. Françès(Navarre Institute of Health Research), Célèste Lebbé(Inserm), Anne‐Geneviève Marcelin(Inserm), Sylvie Euvrard(Hospices Civils de Lyon), Sylvie Chevret(Saint Louis University Hospital), C. Legendre(Délégation Paris 5), A. Bigorie(Agence de la Biomédecine), Élisabeth Dussaix(Université Paris-Sud), Julie Lejeune(Délégation Paris 7), F. Agbalika(Inserm), Thomas F. Schulz(Medizinische Hochschule Hannover)
Cited by 82
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k